Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Basit Öğe Kaydı
dc.contributor.authorIlhan, Yusuf
dc.contributor.authorTatli, Ali Murat
dc.contributor.authorTeker, Fatih
dc.contributor.authorOnder, Arif Hakan
dc.contributor.authorKose, Fatih
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorKaraagac, Mustafa
dc.date.accessioned2024-02-23T14:26:12Z
dc.date.available2024-02-23T14:26:12Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractObjective Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In this study we aimed to evaluate the efficacy of these two regimens for the treatment of metastatic or recurrent cervical cancer. Methods Patients with metastatic or recurrent cervical cancer treated with cisplatin-paclitaxel and bevacizumab or carboplatin-paclitaxel and bevacizumab were retrospectively evaluated in this study. The clinical and demographic characteristics of patients in each group were evaluated. Median overall survival, progression-free survival, and response rates between the two groups were compared. Results A total of 250 patients were included. Overall, the numbers of patients with recurrent disease and metastatic disease were 159 and 91, respectively. The most common histologic subtype was squamous cell carcinoma (83.2%). The median duration of follow-up was 13.6 (range 0.5-86) months. The median progression-free survival was 10.5 (95% CI 9.0 to 11.8) months in the cisplatin-paclitaxel and bevacizumab group (group 1), and 10.8 (95% CI 8.6 to 13.0) months in the carboplatin-paclitaxel and bevacizumab group (group 2) (HR 1.20; 95% CI 0.88 to 1.63; p=0.25). The median overall survival was 19.1 (95% CI 13.0 to 25.1) months in group 1 and 18.3 (95% CI 15.3 to 21.3) months in group 2 (HR 1.28; 95% CI 0.91 to 1.80; p=0.15). Conclusions There is no survival difference between cisplatin or carboplatin combined with paclitaxel and bevacizumab in metastatic or recurrent cervical cancer.en_US
dc.identifier.doi10.1136/ijgc-2021-003165
dc.identifier.endpage507en_US
dc.identifier.issn1048-891X
dc.identifier.issn1525-1438
dc.identifier.issue4en_US
dc.identifier.pmid35086927en_US
dc.identifier.scopus2-s2.0-85128244977en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage502en_US
dc.identifier.urihttps://doi.org/10.1136/ijgc-2021-003165
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14108
dc.identifier.volume32en_US
dc.identifier.wosWOS:000748642300001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmj Publishing Groupen_US
dc.relation.ispartofInternational Journal Of Gynecological Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCervical Canceren_US
dc.titleCisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu